{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:32:32Z","timestamp":1760146352635,"version":"build-2065373602"},"reference-count":81,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T00:00:00Z","timestamp":1730160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathogens"],"abstract":"<jats:p>Introduction: Patients receiving biological and targeted synthetic disease-modifying antirheumatic drugs (b\/tsDMARDs) for rheumatological conditions are at an increased risk of serious, potentially life-threatening, infection. However, the incidence, aetiology, and clinical course of serious infection in patients receiving b\/tsDMARDs in tropical settings are incompletely defined. Methods: We retrospectively reviewed all patients with rheumatoid arthritis receiving b\/tsDMARDs between October 2012 and October 2021, at Cairns Hospital in tropical Australia. The incidence, aetiology, and clinical course of serious infections (those requiring admission to hospital or parenteral antibiotics) were determined. Results: 310 patients had 1468 patient years of b\/tsDMARD therapy during the study period; 74\/310 (24%) had 147 serious infections translating to an overall risk of 10.0 episodes of serious infection per 100 patient years. The respiratory tract (50\/147, 34%) and skin (37\/147, 25%) were the most frequently affected sites. A pathogen was identified in 59\/147 (40%) episodes and was most commonly Staphylococcus aureus (24\/147, 16%). Only 2\/147 (1%) were confirmed \u201ctropical infections\u201d: 1 case of Burkholderia pseudomallei and 1 case of mixed B. pseudomallei and community-acquired Acinetobacter baumannii infection. Overall, 13\/147 (9%) episodes of serious infection required Intensive Care Unit admission (0.9 per 100-patient years of b\/tsDMARD therapy) and 4\/147 (3%) died from their infection (0.3 per 100-patient years of b\/tsDMARD therapy). The burden of comorbidity and co-administration of prednisone were the strongest predictors of death or a requirement for ICU admission. Conclusions: The risk of serious infection in patients taking b\/tsDMARDs in tropical Australia is higher than in temperate settings, but this is not explained by an increased incidence of traditional tropical pathogens.<\/jats:p>","DOI":"10.3390\/pathogens13110943","type":"journal-article","created":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T13:21:39Z","timestamp":1730208099000},"page":"943","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Incidence, Aetiology and Clinical Course of Serious Infections Complicating Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drug Therapy in Patients with Rheumatoid Arthritis in Tropical Australia"],"prefix":"10.3390","volume":"13","author":[{"given":"Cody F.","family":"Price","sequence":"first","affiliation":[{"name":"Department of Medicine, Cairns Hospital, Cairns, QLD 4870, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John P.","family":"Wood","sequence":"additional","affiliation":[{"name":"Department of Medicine, Cairns Hospital, Cairns, QLD 4870, Australia"},{"name":"College of Medicine and Dentistry, James Cook University, Cairns, QLD 4878, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim","family":"Ismail","sequence":"additional","affiliation":[{"name":"Department of Medicine, Cairns Hospital, Cairns, QLD 4870, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Medicine, Cairns Hospital, Cairns, QLD 4870, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1423-3839","authenticated-orcid":false,"given":"Josh","family":"Hanson","sequence":"additional","affiliation":[{"name":"Department of Medicine, Cairns Hospital, Cairns, QLD 4870, Australia"},{"name":"The Kirby Institute, University of New South Wales, Kensington, NSW 2052, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"152249","DOI":"10.1016\/j.semarthrit.2023.152249","article-title":"Comparative effectiveness of treatments for rheumatoid arthritis in clinical practice: A systematic review","volume":"62","author":"Sparks","year":"2023","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_2","first-page":"CD008794","article-title":"Adverse effects of biologics: A network meta-analysis and Cochrane overview","volume":"2011","author":"Singh","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.rdc.2012.08.019","article-title":"Infections and biologic therapy in rheumatoid arthritis: Our changing understanding of risk and prevention","volume":"38","author":"Winthrop","year":"2012","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0140-6736(14)61704-9","article-title":"Risk of serious infection in biological treatment of patients with rheumatoid arthritis: A systematic review and meta-analysis","volume":"386","author":"Singh","year":"2015","journal-title":"Lancet"},{"key":"ref_5","unstructured":"(2024, May 03). Primary Prophylaxis in Immunocompromised Adults Without HIV Infection Melbourne: Therapeutic Guidelines. Available online: https:\/\/www.tg.org.au."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.semarthrit.2016.10.010","article-title":"Systematic review of rheumatic disease epidemiology in the indigenous populations of Canada, the United States, Australia, and New Zealand","volume":"46","author":"McDougall","year":"2017","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_7","first-page":"526","article-title":"Prevention of opportunistic infections in immunosuppressed patients in the tropical top end of the Northern Territory","volume":"27","author":"Davis","year":"2003","journal-title":"Commun. Dis. Intell. Q. Rep."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Prinsloo, C., Smith, S., Law, M., and Hanson, J. (2023). The Epidemiological, Clinical, and Microbiological Features of Patients with Burkholderia pseudomallei Bacteraemia-Implications for Clinical Management. Trop. Med. Infect. Dis., 8.","DOI":"10.3390\/tropicalmed8110481"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Smith, S., Kennedy, B.J., Dermedgoglou, A., Poulgrain, S.S., Paavola, M.P., Minto, T.L., Luc, M., Liu, Y.H., and Hanson, J. (2019). A simple score to predict severe leptospirosis. PLoS Negl. Trop. Dis., 13.","DOI":"10.1371\/journal.pntd.0007205"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Stewart, A.G.A., Smith, S., Binotto, E., McBride, W.J.H., and Hanson, J. (2019). The epidemiology and clinical features of rickettsial diseases in North Queensland, Australia: Implications for patient identification and management. PLoS Negl. Trop. Dis., 13.","DOI":"10.1371\/journal.pntd.0007583"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"339","DOI":"10.4269\/ajtmh.19-0490","article-title":"Rapid Progress toward Elimination of Strongyloidiasis in North Queensland, Tropical Australia, 2000\u20132018","volume":"102","author":"Paltridge","year":"2020","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"245","DOI":"10.4269\/ajtmh.17-0004","article-title":"Case Report: Endemic Amebiasis in Australia: Implications for Residents, Travelers, and Clinicians","volume":"97","author":"Smith","year":"2017","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Sim, B.Z., Conway, L., Smith, L.K., Fairhead, L., Der, Y.S., Payne, L., Binotto, E., Smith, S., and Hanson, J. (2022). The aetiology and clinical characteristics of cryptococcal infections in Far North Queensland, tropical Australia. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0265739"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/imj.13994","article-title":"Tuberculosis in Far North Queensland, Australia: A retrospective clinical audit","volume":"49","author":"Wilson","year":"2019","journal-title":"Intern. Med. J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/j.1445-2197.2010.05338.x","article-title":"Mycobacterium ulcerans infection in North Queensland: The \u2018Daintree ulcer\u2019","volume":"80","author":"Steffen","year":"2010","journal-title":"ANZ J. Surg."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"182","DOI":"10.5694\/mja2.50243","article-title":"Leprosy in Far North Queensland: Almost gone, but not to be forgotten","volume":"211","author":"Hempenstall","year":"2019","journal-title":"Med. J. Aust."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Fairhead, L.J., Smith, S., Sim, B.Z., Stewart, A.G., Stewart, J.D., Binotto, E., Law, M., and Hanson, J. (2022). The seasonality of infections in tropical Far North Queensland, Australia: A 21-year retrospective evaluation of the seasonal patterns of six endemic pathogens. PLoS Glob. Public Health, 2.","DOI":"10.1371\/journal.pgph.0000506"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijid.2022.12.015","article-title":"The efficacy and safety of a shortened duration of antimicrobial therapy for Group A Streptococcus bacteraemia","volume":"128","author":"Nguyen","year":"2022","journal-title":"Int. J. Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Gora, H., Smith, S., Wilson, I., Preston-Thomas, A., Ramsamy, N., and Hanson, J. (2022). The epidemiology and outcomes of central nervous system infections in Far North Queensland, tropical Australia; 2000\u20132019. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0265410"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/1753-6405.12808","article-title":"The Indo-Papuan conduit: A biosecurity challenge for Northern Australia","volume":"42","author":"Horwood","year":"2018","journal-title":"Aust. N. Z. J. Public Health"},{"key":"ref_21","unstructured":"(2024, October 27). Socio-Economic Indexes for Areas (SEIFA), Australia Canberra: Australian Bureau of Statistics, Available online: https:\/\/www.abs.gov.au\/statistics\/people\/people-and-communities\/socio-economic-indexes-areas-seifa-australia\/latest-release."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Kang, K., Chau, K.W., Howell, E., Anderson, M., Smith, S., Davis, T.J., Starmer, G., and Hanson, J. (2021). The temporospatial epidemiology of rheumatic heart disease in Far North Queensland, tropical Australia 1997-2017; impact of socioeconomic status on disease burden, severity and access to care. PLoS Negl. Trop. Dis., 15.","DOI":"10.1371\/journal.pntd.0008990"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Hanson, J., Smith, S., Stewart, J., Horne, P., and Ramsamy, N. (2021). Melioidosis-a disease of socioeconomic disadvantage. PLoS Negl. Trop. Dis., 15.","DOI":"10.1371\/journal.pntd.0009544"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijid.2022.02.026","article-title":"Animal bite wounds and their management in tropical Australia","volume":"118","author":"Vardanega","year":"2022","journal-title":"Int. J. Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Hanson, J., Fox, M., Anderson, A., Fox, P., Webster, K., Williams, C., Nield, B., Bagshaw, R., Hempenstall, A., and Smith, S. (2020). Chronic hepatitis B in remote, tropical Australia; successes and challenges. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0238719"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.pathol.2018.11.015","article-title":"Increasing prevalence of methicillin-resistant Staphylococcus aureus in remote Australian communities: Implications for patients and clinicians","volume":"51","author":"Guthridge","year":"2019","journal-title":"Pathology"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Hanson, J., Smith, S., Brooks, J., Groch, T., Sivalingam, S., Curnow, V., Carter, A., and Hargovan, S. (2020). The applicability of commonly used predictive scoring systems in Indigenous Australians with sepsis: An observational study. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0236339"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s10096-023-04641-6","article-title":"The aetiology and incidence of infective endocarditis in people living with rheumatic heart disease in tropical Australia","volume":"42","author":"Basaglia","year":"2023","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"41","DOI":"10.33321\/cdi.2023.47.41","article-title":"A low burden of severe illness: The COVID-19 Omicron outbreak in the remote Torres and Cape region of Far North Queensland","volume":"47","author":"Taunton","year":"2023","journal-title":"Commun. Dis. Intell."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J. Chronic Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.idc.2012.02.007","article-title":"Tropical diseases: Definition, geographic distribution, transmission, and classification","volume":"26","author":"Zumla","year":"2012","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e00833","DOI":"10.1016\/j.idcr.2020.e00833","article-title":"Polymicrobial community-acquired Acinetobacter baumannii and Burkholderia pseudomallei bacteremia: Opportunistic infections with similar risk factors in northern Australia","volume":"21","author":"Fairhead","year":"2020","journal-title":"IDCases"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1136\/ard.2011.151043","article-title":"Treatment benefit or survival of the fittest: What drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?","volume":"70","author":"Strangfeld","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.semarthrit.2012.05.004","article-title":"Risk of mortality, fatal infection, and fatal malignancy related to use of anti-tumor necrosis factor-alpha biologics by rheumatoid arthritis patients","volume":"42","author":"Thyagarajan","year":"2012","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"257","DOI":"10.4269\/ajtmh.21-0615","article-title":"The Applicability of Commonly Used Severity of Illness Scores to Tropical Infections in Australia","volume":"106","author":"Salaveria","year":"2021","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_36","unstructured":"(2024, October 27). Determinants of Health for First Nations People Canberra: Australian Institute of Health and Welfare. Australian Government, Available online: https:\/\/www.aihw.gov.au\/reports\/australias-health\/social-determinants-and-indigenous-health."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1097\/01.CCM.0000239114.50519.0E","article-title":"The role of infection and comorbidity: Factors that influence disparities in sepsis","volume":"34","author":"Esper","year":"2006","journal-title":"Crit. Care Med."},{"key":"ref_38","unstructured":"Australian Institute of Health and Welfare\u2014Australian Government (2024). Aboriginal and Torres Strait Islander Health Performance Framework: Summary Report August 2024."},{"key":"ref_39","first-page":"3371","article-title":"Communicable diseases in rural and remote Australia: The need for improved understanding and action","volume":"15","author":"Quinn","year":"2015","journal-title":"Rural Remote Health"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1002\/art.10524","article-title":"Frequency of infection in patients with rheumatoid arthritis compared with controls: A population-based study","volume":"46","author":"Doran","year":"2002","journal-title":"Arthritis Rheum."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"129","DOI":"10.31138\/mjr.31.1.129","article-title":"Infections in Patients with Rheumatoid Arthritis in the Era of Targeted Synthetic Therapies","volume":"31","author":"Thomas","year":"2020","journal-title":"Mediterr. J. Rheumatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/rheumatology\/keq242","article-title":"Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: Updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly","volume":"50","author":"Galloway","year":"2011","journal-title":"Rheumatology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2011.1692","article-title":"Initiation of tumor necrosis factor-alpha antagonists and the risk of hospitalization for infection in patients with autoimmune diseases","volume":"306","author":"Grijalva","year":"2011","journal-title":"JAMA"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Bellan, M., Scotti, L., Ferrante, D., Calzaducca, E., Manfredi, G.F., Sainaghi, P.P., and Barone-Adesi, F. (2022). Risk of Severe Infection among Rheumatoid Arthritis Patients on Biological DMARDs: A Population-Based Cohort Study. J. Clin. Med., 11.","DOI":"10.3390\/jcm11112955"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1136\/annrheumdis-2011-200702","article-title":"Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: A nested case-control analysis","volume":"71","author":"Dixon","year":"2012","journal-title":"Ann. Rheum Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s42358-024-00363-1","article-title":"Predictors of serious infections in rheumatoid arthritis-a prospective Brazilian cohort","volume":"64","author":"Pereira","year":"2024","journal-title":"Adv. Rheumatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1136\/ard.2010.128637","article-title":"High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis","volume":"70","author":"Au","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1136\/annrheumdis-2020-eular.1137","article-title":"SAT0581\u2005Serious Infection Rates with Biological Disease Modifying Anti-Rheumatic Agents (bDMARDs) and Presdisposing Factors: A 5-Year Retrospective Review","volume":"79","author":"Celkys","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_49","first-page":"905","article-title":"Serious infection across biologic-treated patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis","volume":"77","author":"Rutherford","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s11926-021-01037-3","article-title":"Long-Term Safety of Rituximab (Risks of Viral and Opportunistic Infections)","volume":"23","author":"Varley","year":"2021","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1136\/annrheumdis-2018-214326","article-title":"Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden","volume":"78","author":"Arkema","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.autrev.2017.11.015","article-title":"Clinical and microbiological characteristics of the infections in patients treated with rituximab for autoimmune and\/or malignant hematological disorders","volume":"17","author":"Tudesq","year":"2018","journal-title":"Autoimmun. Rev."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1513\/AnnalsATS.201612-994OI","article-title":"Notification of Nontuberculous Mycobacteria: An Australian Perspective","volume":"14","author":"Thomson","year":"2017","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1071\/PY22142","article-title":"Community antibiotic management of skin infections in the Torres Strait","volume":"29","author":"Hempenstall","year":"2023","journal-title":"Aust. J. Prim. Health"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Townend, R., Smith, S., and Hanson, J. (2024). Microbiological and clinical features of patients with cellulitis in tropical Australia; disease severity assessment and implications for clinical management. Am. J. Trop. Med. Hyg., in press.","DOI":"10.4269\/ajtmh.24-0450"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1111\/coa.13451","article-title":"The microbiology of ear cultures in a high-burden setting in tropical Australia: Implications for clinicians","volume":"44","author":"Nofz","year":"2019","journal-title":"Clin. Otolaryngol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s10096-022-04542-0","article-title":"A multi-centre retrospective study of Nocardia speciation and antimicrobial susceptibility in Queensland, Australia","volume":"42","author":"Sim","year":"2023","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Parisi, A., Crump, J.A., Stafford, R., Glass, K., Howden, B.P., and Kirk, M.D. (2019). Increasing incidence of invasive nontyphoidal Salmonella infections in Queensland, Australia, 2007\u20132016. PLoS Negl. Trop. Dis., 13.","DOI":"10.1371\/journal.pntd.0007187"},{"key":"ref_59","first-page":"604","article-title":"Tropical and exotic dermatoses and ulcers","volume":"43","author":"Rathnayake","year":"2014","journal-title":"Aust. Fam. Physician"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.3201\/eid2011.131315","article-title":"Foodborne illness, Australia, circa 2000 and circa 2010","volume":"20","author":"Kirk","year":"2014","journal-title":"Emerg. Infect. Dis."},{"key":"ref_61","unstructured":"Chief Health Officer Branch (2013). Review of the Prevention and Control of Legionella pneumophila Infection in Queensland, Chief Health Officer\u2019s Report."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s12072-021-10239-x","article-title":"APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy","volume":"15","author":"Lau","year":"2021","journal-title":"Hepatol. Int."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1128\/CMR.17.4.770-782.2004","article-title":"Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients","volume":"17","author":"Rodriguez","year":"2004","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"544","DOI":"10.5694\/mja2.51739","article-title":"Invasive group A streptococcal disease in the Northern Territory and the impact of melioidosis antibiotic prophylaxis","volume":"217","author":"Birrell","year":"2022","journal-title":"Med. J. Aust."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ekir.2017.09.005","article-title":"Trimethoprim+Sulfamethoxazole Reduces Rates of Melioidosis in High-Risk Hemodialysis Patients","volume":"3","author":"Majoni","year":"2018","journal-title":"Kidney Int. Rep."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"ofae431","DOI":"10.1093\/ofid\/ofae431","article-title":"Lower Rates of Staphylococcus aureus Bloodstream Infection in Patients on Hemodialysis Receiving Trimethoprim-Sulfamethoxazole Melioidosis Prophylaxis","volume":"11","author":"Bryce","year":"2024","journal-title":"Open Forum Infect. Dis."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11882-002-0033-y","article-title":"Allergic adverse reactions to sulfonamides","volume":"2","author":"Vial","year":"2002","journal-title":"Curr. Allergy Asthma Rep."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/1346-8138.15724","article-title":"Adverse effects of trimethoprim-sulfamethoxazole for the prophylaxis of Pneumocystis pneumonia in dermatology","volume":"48","author":"Kokubu","year":"2021","journal-title":"J. Dermatol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s13075-019-1996-6","article-title":"Pneumocystis pneumonia in patients with rheumatic diseases receiving prolonged, non-high-dose steroids-clinical implication of primary prophylaxis using trimethoprim-sulfamethoxazole","volume":"21","author":"Park","year":"2019","journal-title":"Arthritis Res. Ther."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/jcpt.12060","article-title":"Methotrexate and trimethoprim-sulphamethoxazole: Extremely serious and life-threatening combination","volume":"38","year":"2013","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.3201\/eid2712.211302","article-title":"Increased Incidence of Melioidosis in Far North Queensland, Queensland, Australia, 1998\u20132019","volume":"27","author":"Smith","year":"2021","journal-title":"Emerg. Infect. Dis."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Herbert, D.R., Stoltzfus, J.D.C., Rossi, H.L., and Abraham, D. (2022). Is Strongyloides stercoralis hyperinfection induced by glucocorticoids a result of both suppressed host immunity and altered parasite genetics?. Mol. Biochem. Parasitol., 251.","DOI":"10.1016\/j.molbiopara.2022.111511"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S1473-3099(19)30289-0","article-title":"Multiple-dose versus single-dose ivermectin for Strongyloides stercoralis infection (Strong Treat 1 to 4): A multicentre, open-label, phase 3, randomised controlled superiority trial","volume":"19","author":"Buonfrate","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1002\/art.21386","article-title":"Infections in patients with rheumatoid arthritis treated with biologic agents","volume":"52","author":"Listing","year":"2005","journal-title":"Arthritis Rheum."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1002\/art.22808","article-title":"Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: Lessons from interpreting data from observational studies","volume":"56","author":"Dixon","year":"2007","journal-title":"Arthritis Rheum."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s40265-024-02059-8","article-title":"Biologics or Janus Kinase Inhibitors in Rheumatoid Arthritis Patients Who are Insufficient Responders to Conventional Anti-Rheumatic Drugs","volume":"84","author":"Favalli","year":"2024","journal-title":"Drugs"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"162","DOI":"10.55563\/clinexprheumatol\/cpu6r9","article-title":"Prevention and management of herpes zoster in patients with rheumatoid arthritis and psoriatic arthritis: A clinical review","volume":"40","author":"Winthrop","year":"2022","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"597","DOI":"10.4269\/ajtmh.18-0421","article-title":"Antibiotic Prophylaxis for Melioidosis in Patients Receiving Hemodialysis in the Tropics? One Size Does Not Fit All","volume":"99","author":"Chau","year":"2018","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.idc.2021.03.011","article-title":"Histoplasmosis","volume":"35","author":"Arauz","year":"2021","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e1618","DOI":"10.1016\/S2214-109X(21)00350-8","article-title":"A global call for talaromycosis to be recognised as a neglected tropical disease","volume":"9","author":"Narayanasamy","year":"2021","journal-title":"Lancet Glob. Health"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1002\/art.20454","article-title":"Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists","volume":"50","author":"Bergstrom","year":"2004","journal-title":"Arthritis Rheum."}],"container-title":["Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-0817\/13\/11\/943\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:23:31Z","timestamp":1760113411000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-0817\/13\/11\/943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,29]]},"references-count":81,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["pathogens13110943"],"URL":"https:\/\/doi.org\/10.3390\/pathogens13110943","relation":{},"ISSN":["2076-0817"],"issn-type":[{"type":"electronic","value":"2076-0817"}],"subject":[],"published":{"date-parts":[[2024,10,29]]}}}